340B Program Cost States $2 Billion in Foregone Medicaid Rebates in 2023, Analysis Finds

When 340B covered entities shift hospital outpatient drug claims from Medicaid into the 340B program, state Medicaid programs lose access to manufacturer rebates—totaling an estimated $2 billion in 2023 alone. The analysis highlights how rapid 340B growth, particularly among rural referral centers and disproportionate share hospitals, creates budget pressure for state Medicaid programs while patients may not receive direct cost-sharing relief. This matters for MCO compliance and finance teams navigating drug pricing arrangements and state directors managing pharmacy budgets under constrained fiscal conditions.

Pharmacy · Finance · Managed Care

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere